In particular, antibodies targeting immune checkpoint protein programmed death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) have been approved by the Food and Drug Administration (FDA) to treat 25 types of cancers in over 120 000 patients [4]. The gene discussed is CD274; the disease is cancer.